Background {#Sec1}
==========

Esophageal cancer (or oesophageal cancer), a type of cancer arising from the esophagus, is the eighth most common cancer and the sixth leading cause of cancer-related death worldwide \[[@CR1]\]. Squamous cell carcinomas (SCC), which is more common in the developing world, and adenocarcinomas (AC), which is more common in the developed world, are two main forms of histologically confirmed esophageal cancer \[[@CR2], [@CR3]\]. The clinical symptoms include difficulty in swallowing, enlarged lymph glands around the collarbone, a dry cough, weight loss, and possibly hematemesis \[[@CR4]\]. The established risk factors for this disease are environmental factors (alcohol drinking, smoking, infecting bacteria or virus), genetic factors (mutations in enzymes that metabolize alcohol), cultural factors (high-temperature food items such as pork braised in brown sauce and old stocked rice), obesity and gastroesophageal reflux \[[@CR5]--[@CR8]\]. The incidence of esophageal cancer is threefold higher in men than women \[[@CR9]\] and is high in east Asia, southern Africa, and southern Europe while is low in North America and other parts of Europe \[[@CR10]\]. The highest reported incidence and mortality rates occur in China, which is almost 20 to 30 times higher than that in the USA \[[@CR11]\]. According to cancer statistics, there will be an estimated 16,980 new cases and 15,590 deaths in both sexes in the USA in 2015 \[[@CR12]\]. Although many advances in diagnosis and treatment such as endoscopic resection, chemotherapy, and surgery have the potential to substantially reduce mortality and morbidity \[[@CR13], [@CR14]\], the prognosis of patients with esophageal cancer remains poor and the 5-year survival rate is still low, ranging from 15 to 25 % \[[@CR15], [@CR16]\]. Therefore, identifying new biomarkers for early diagnosis and treatment is vital to decide therapeutic options, improve treatment efficiency, and predict prognosis \[[@CR17]\].

Evidences have shown that gene polymorphisms may play an important role in the carcinogenesis of esophageal cancer \[[@CR18]\]. Alcohol dehydrogenase gene (ADH), at chromosome 4, is a key cytosolic enzyme for ethanol \[[@CR19]\]. It encodes at least seven ADH isoforms (ADH1--ADH7), each with slightly different properties \[[@CR20]\], and may be involved in the metabolic pathways of several neurotransmitters \[[@CR21]\]. The ADH1B (also known as ADH2) gene is located on human chromosome 4q21-q23. It is the locus responsible for most of the ADH activity on ethanol in the liver \[[@CR22]\]. Single nucleotide polymorphisms (SNPs) occurring in this gene may be capable of altering ethanol metabolism, and individuals expressing the ADH1B variants would have different alcohol elimination rates \[[@CR23]\]. One of the most studied SNP was Arg47His (rs1229984), a G to A base transition in exon 3 leading to the substitution of arginine (ADH1B\*1) to histidine (ADH1B\*2) at codon 47th position. ADH1B\*2 is common in more than 90 % of Asians and reduced their risk for alcoholism but fewer than 20 % of Caucasians or Africans \[[@CR24]\]. This variant was shown to be strongly associated with alcohol dependence, abuse, consumption, and alcohol-induced liver diseases \[[@CR25], [@CR26]\].

Several studies have identified the relationship between ADH1B polymorphism and esophageal cancer susceptibility, but the consistent results were not obtained. For example, Ito et al. demonstrated that ADH1B Arg47His variant was associated with esophageal cancer in Japanese and might be used in personalized prevention programs \[[@CR27]\], while Ma et al. did not show significant associations between variations in the ADH1B gene and esophageal squamous cell carcinoma (ESCC) risk in Chinese \[[@CR28]\]. Although previous meta-analyses were performed to evaluate this association \[[@CR29]--[@CR31]\], limited articles were selected, only Asian population was used for analysis, and some repeated participants were included. Furthermore, Asians and Caucasians may have different incidence, distribution, and susceptibilities to esophageal cancer due to different heritage backgrounds \[[@CR32]\]. All these factors may influence the reliable of the results. Therefore, we conducted the present meta-analysis to review all the published articles among any ethnicities to obtain a relative reliable result.

Methods {#Sec2}
=======

Identification of relevant studies {#Sec3}
----------------------------------

Electronic databases of PubMed, Web of Science, Medline, Embase, CNKI (China National Knowledge Internet), and Wanfang were comprehensively searched to retrieve relevant articles published between January 2000 and June 2015. The MeSH terms were as follows: "esophageal cancer or oesophageal cancer or esophageal squamous cell carcinomas or esophageal adenocarcinomas," "alcohol dehydrogenase or ADH1B or ADH2," and "polymorphism or variant or mutation" as well as their combinations. The equivalent Chinese characters were used in Chinese database. We also manually searched the references of included studies in order to obtain more related articles. Our analysis only considered studies that were written in English and Chinese.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

The eligible articles must meet the following criteria. The inclusion criteria were as follows: (1) case-control studies evaluating the correlation of ADH1B Arg47His polymorphism in esophageal cancer occurrence; (2) patents with esophageal cancer should be diagnosed clinically and confirmed histologically, the controls should be age-, ethnicity-matched participants without malignancy and digestive and chronic diseases; (3) the genotype information were available to extract; and (4) the genotypes of controls were consistent with Hardy-Weinberg equilibrium (HWE). The exclusion criteria were as follows: (1) duplicate articles from the same authors or laboratories or conducted among the same populations; (2) conference reports or reviews; (3) without control group; and (4) data could not be extracted.

Data extraction {#Sec5}
---------------

Two of our authors independently assessed the quality of selected studies. Each item of a single study should be achieved a final consensus. The extracted information was as follow: the name of first author, published year, country, ethnicity, mean age, sample size, genotype method, alleles and genotypes distribution, source of cases and controls, and HWE of genotypes in controls.

Statistical analysis {#Sec6}
--------------------

The pooled odds ratio (OR) with its 95 % confidence interval (CI) were employed to estimate the association between ADH1B Arg47His variant and esophageal carcinoma susceptibility. The *Z* test was used to determine the significance of ORs, and *P* value was less than 0.05 considered as statistically significance. The allelic model (His vs. Arg), the homologous model (His/His vs. Arg/Arg), the heterogeneous model (Arg/His vs. Arg/Arg), the dominant model (His/His+Arg/His vs. Arg/Arg) and the recessive model (His/His vs. Arg/His+Arg/Arg) were examined. The *Q* test and the *I*^2^ test were used to assess the degree and proportion of between-study heterogeneity, respectively. The fixed-effect model was used when the *P* value of the *Q* test was more than 0.10 and the *I*^2^ of the *I*^2^ test was less than 50 %; otherwise, the random-effect model was used. All statistical analyses were conducted in Review Manager 5.2 (the Cochrane Collaboration, Oxford, England). All the tests were two-sided.

Results {#Sec7}
=======

Characteristics of included studies {#Sec8}
-----------------------------------

We firstly identified 105 articles. After the inclusion and exclusion criteria filtering, a total of 23 relevant articles were finally screened out, including 9338 esophageal cancer patients and 14,896 matched controls. Figure [1](#Fig1){ref-type="fig"} presented the selection process. Of the 23 articles, two were written in Chinese \[[@CR33], [@CR34]\] and 21 were in English \[[@CR35]--[@CR55]\]. The participants of Hashibe et al.'s study were from five countries (Romania, Poland, Russia, Slovakia, and Czech Republic) \[[@CR38]\], while other studies were from seven countries (Japan, Thailand, Iran, Kashmir, Sudan, Dutch and China), respectively. There were two sources of controls: population-based controls and hospital-based controls. The ADH1B Arg47His variant was measured in eight methods. Table [1](#Tab1){ref-type="table"} listed the main characteristics of included studies. Table [2](#Tab2){ref-type="table"} displayed the alleles and genotypes information of ADH1B Arg47His variant in each included studies.Fig. 1Flow diagram of the selection processTable 1Main characteristics of included studies in this meta-analysisFirst authorYearCountryEthnicityMean ageSample sizeSource ofGenotyping methodsCasesControlsCasesControlsCasesControlsYokoyama A2001JapanAsian56 ± 753 ± 8112526ESCCHBPCR-RFLPBoonyaphiphat P2002ThailandAsian64.0 ± 9.764.5 ± 12.3202261ESCCHBAPLPChao YC2003China (Taiwan)Asian64.6 ± 12.353.0 ± 18.888105ECHBPCR-RFLPYokoyama T2003JapanAsian61.7 ± 7.958.9 ± 7.1233610ESCCPBPCR-RFLPChen HG2005ChinaAsian58.06 (35--80)58.53 (35--82)137137ECPBPCRYang CX2005JapanAsian61.4 ± 0.661.4 ± 0.4165495ESCC/EACHBPCR-CTPPHashibe M2006MixedCaucasian56.7 ± 2.158.9 ± 3.4167887ESCCPBTaqManYang SJ2007ChinaAsian58.3 ± 8.352.8 ± 13.2191198ECPBPCR-CTPPGuo YM2008ChinaAsian60.2 ± 8.959.7 ± 9.780480ESCCPBPCR-RFLPLee CH2008China (Taiwan)Asian60.2 ± 3.861.3 ± 3.9406656ESCCHBPCR-RFLPAkbai2009IranAsian63.6 (25--89)55.2 (24--90)7461373ESCCPBSequenomCui R2009JapanAsian64.2 ± 8.759.7 ± 16.210702836ESCCPBBeadChipDing JH2010ChinaAsian68.2 ± 5.669.8 ± 7.3221191ECPBPCR-DHPLCTanaka F2010JapanAsian67.2 ± 7.366.5 ± 7.2742820OSCCPBBRLMMIqbal B2011KashmirAsianNANA5050ECPBSequencingWang YL2011ChinaAsian57.2 ± 9.456.1 ± 7.381162ECPBPCR-CTPPGu HY2012ChinaAsian62.5 ± 6.263.8 ± 7.1380380ESCCHBMALDI-ToF-MSDura P2013DutchCaucasian65.0 ± 10.964.9 ± 11.1351430ESCC/EACPBTaqManGao Y2013ChinaAsianNANA21392273ESCCPBTaqManWu M2013ChinaAsian63.7 ± 9.463.7 ± 10.38461079ECPBSequencingHou AM2014ChinaAsian56.5 ± 5.558.7 ± 6.3110110ESCC/EACPBPCR-RFLPYe B2014ChinaAsian58.7 ± 6.459.9 ± 7.210011391ESCCHBPCR-RFLPBabiker H2015SudanAfrica56.4147.87134233ESCC/EACPBPCR-RFLP*NA* not available, *ESCC* esophageal squamous cell carcinoma, *EAC* esophageal adenocarcinoma, *OSCC* oesophageal squamous cell carcinoma, *HB* hospital-based, *PB* population-based, *NP* normal healthy population, *APLP* amplified product length polymorphism method, *PCR-CTPP* polymerase chain reaction with the confronting two-pair primer, *PCR-DHPLC* polymerase chain reaction and denaturing high-performance liquid chromatography, *BRLMM* Bayesian robust linear model with Mahalanobis algorithm, *MALDI-ToF-MS* matrix-assisted laser desorption/ionization-time-of-flight mass spectrometryTable 2Distribution of alleles and genotypes in each included studiesFirst authorCasesControlsArg/ArgArg/HisHis/HisArgHisArg/ArgArg/HisHis/HisArgHisHWE(\*1/\*1)(\*1/\*2),(\*2/\*2)(\*1)(\*2)(\*1/\*1)(\*1/\*),(\*2/\*2)(\*1)(\*2)Yokoyama A5656\*----145381\*----Boonyaphiphat P101861528811694139283271950.08Chao YC194128799774355571530.94Yokoyama T5173109175291312123672749460.99Chen HG265457106168144974771970.40Yang CX6857497233221683042127760.98Hashibe M1634\*----79295\*------Yang SJ33807814623622761001202760.44Guo YM17253859101241682882167440.99Lee CH117149140383429462753353679450.59Akbai2123249027412127347182761721250.86Cui R19436351075113831519861626128842380.99Ding JH1996106134308875108912910.53Tanaka F1492373565359494928748438512550.76Iqbal B1236260401237161390.30Wang YL153433641001767781012230.90Gu HY53168158274484261701822225340.26Dura P32620067220406230835230.85Gao Y252907939141127851999091155130732190.57Wu M138309355585101910141051061214300.38Hou AM59\*51----48\*62------Ye B224400377848115415057866387819040.36Babiker H1158223812188184394260.06*HWE* Hardy-Weinberg Equilibrium;--, not applicable; \*for Yokoyama A and Hashibe M means His/His+Arg/His; \*for Hou AM means Arg/His+Arg/Arg

Overall association between ADH1B Arg47His polymorphism and esophageal cancer risk {#Sec9}
----------------------------------------------------------------------------------

A significant heterogeneity among all the included studies was observed (*P* \< 0.01 and *I*^2^ \> 50 %), and the random-effect model was used. Table [3](#Tab3){ref-type="table"} listed the results of the association between the ADH1B Arg47His polymorphism and esophageal cancer susceptibility. Overall, we found that the frequency of 47His allele was higher than the 47Arg allele in both cases and controls, and the statistical analysis demonstrated that the 47His allele was significant associated with the decreased risk of esophageal cancer in total populations (His vs. Arg: OR = 0.67, 95 % CI = 0.59--0.76, *P* \< 0.00001) as shown in Fig. [2](#Fig2){ref-type="fig"}. This significant protective relationship was also identified under other genetic models (*P* \< 0.00001). Subgroup analysis by ethnicity showed that this polymorphism revealed an ethnic difference and geographic variance. In Asians, ADH1B 47His variant was shown to be associated with the decreased esophageal cancer risk under all the genetic models (*P* \< 0.00001); while in non-Asians, no significant correlation was detected in any genetic models (*P* \> 0.05). Figure [3](#Fig3){ref-type="fig"} showed the result of the His carriers of the His/His and Arg/His genotypes compared with the Arg/Arg genotype in both groups. Furthermore, we also considered the role of this genetic variant in esophageal cancer among different countries. There were 12 articles in China (5485 patients and 6982 controls), five in Japan (2319 patients and 5213 controls), and six in other countries. Our result demonstrated that ADH1B Arg47His variant was a protective factor for cancer risk in Chinese and Japanese populations as shown in Fig. [4](#Fig4){ref-type="fig"}.Table 3Meta-analysis of the overall association between ADH1B Arg47His polymorphism and esophageal cancer riskClassificationComparisonsNumber of included studiesTest of associationTest of heterogeneityOR (95 % CI)*P*PhI^2^ModelTotalHis vs. Arg200.67 (0.59, 0.76)\<0.00001\<0.0000187 %RHis/His vs. Arg/Arg200.40 (0.30, 0.54)\<0.00001\<0.0000186 %RArg/His vs. Arg/Arg200.52 (0.40, 0.68)\<0.00001\<0.0000185 %RHis/His+Arg/His vs. Arg/Arg220.46 (0.36, 0.59)\<0.00001\<0.0000186 %RHis/His vs. Arg/His+Arg/Arg210.69 (0.61, 0.77)\<0.00001\<0.0000169 %RAsianHis vs. Arg180.66 (0.57, 0.75)\<0.00001\<0.0000188 %RHis/His vs. Arg/Arg180.40 (0.30, 0.54)\<0.00001\<0.0000187 %RArg/His vs. Arg/Arg180.49 (0.38, 0.65)\<0.00001\<0.0000186 %RHis/His+Arg/His vs. Arg/Arg190.44 (0.34, 0.58)\<0.00001\<0.0000187 %RHis/His vs. Arg/His+Arg/Arg190.68 (0.61, 0.77)\<0.00001\<0.0000171 %RNon-AsianHis vs. Arg20.93 (0.59, 1.47)0.750.460 %FHis/His vs. Arg/Arg10.82 (0.15, 4.53)0.82NANAArg/His vs. Arg/Arg20.95 (0.57, 1.56)0.830.460 %FHis/His+Arg/His vs. Arg/Arg30.59 (0.23, 1.48)0.260.0275 %RHis/His vs. Arg/His+Arg/Arg10.84 (0.15, 4.64)0.84NANAChinaHis vs. Arg110.64 (0.56, 0.73)\<0.00001\<0.0000178 %RHis/His vs. Arg/Arg110.37 (0.29, 0.50)\<0.00001\<0.0000179 %RArg/His vs. Arg/Arg110.47 (0.35, 0.63)\<0.00001\<0.0000177 %RHis/His+Arg/His vs. Arg/Arg110.41 (0.31, 0.55)\<0.00001\<0.0000180 %RHis/His vs. Arg/His+Arg/Arg120.71 (0.66, 0.76)\<0.000010.1629 %FJapanHis vs. Arg40.55 (0.51, 0.60)\<0.000010.410 %FHis/His vs. Arg/Arg40.26 (0.18, 0.38)\<0.000010.0366 %RArg/His vs. Arg/Arg40.35 (0.21, 0.59)\<0.000010.000882 %RHis/His+Arg/His vs. Arg/Arg50.31 (0.22, 0.44)\<0.000010.00474 %RHis/His vs. Arg/His+Arg/Arg40.62 (0.56, 0.69)\<0.000010.650 %F*NA* not applicable, *OR* odds ratio, *95 % CI* 95 % confidence interval, *Ph and I* ^*2*^ test of heterogeneity, *F* fixed-effect model, *R* random-effect modelFig. 2Meta-analysis of ADH1B Arg47His polymorphism and esophageal cancer risk in a random-effect model under the allelic models (His vs. Arg)Fig. 3Subgroup analysis by ethnicity of ADH1B Arg47His polymorphism and esophageal cancer susceptibility under the dominant model (His/His+Arg/His vs. Arg/Arg)Fig. 4Association between ADH1B Arg47His polymorphism and esophageal cancer under the dominant model based on countries

Combined effect of ADH1B Arg47His variant and alcohol drinking, tobacco smoking, and gender difference on esophageal cancer risk {#Sec10}
--------------------------------------------------------------------------------------------------------------------------------

Fifteen studies estimated the combined effect of ADH1B Arg47His polymorphism and alcohol drinking on esophageal cancer risk. However, the relevant data could be extracted only from 12 studies, including 3545 patients and 6909 controls. Based on these data, we could only assess the combined effect on esophageal cancer susceptibility under the Arg/Arg versus His/His+Arg/His model. We divided the subjects into two groups: non-drinking group (1134 cases and 3526 controls) and drinking group (2411 cases and 3383 controls). Our results found that Arg/Arg genotype compared with the His carrier of His/His and Arg/His genotypes was significantly associated with the increased higher risk of esophageal cancer in the drinking group (OR = 3.15, 95 % CI = 2.66--3.74, *P* \< 0.00001) and lower in the non-drinking group (OR = 1.71, 95 % CI = 1.23--2.38, *P* = 0.001) as shown in Fig. [5](#Fig5){ref-type="fig"}.Fig. 5Forest plot of the combined effect of ADH1B Arg47His polymorphism and alcohol drinking condition and esophageal cancer risk under the Arg/Arg versus Arg/His+His/His model (**a** non-drinkers; **b** drinkers)

Four articles considered the combined effect of ADH1B Arg47His polymorphism and tobacco smoking on esophageal cancer susceptibility, containing 2382 patients and 4792 controls. Our result demonstrated that the Arg/Arg genotype was associated with esophageal cancer occurrence in both non-smokers (OR = 2.40, 95 % CI = 1.44--3.98, *P* = 0.0007) and smokers (OR = 3.35, 95 % CI = 2.22--5.05, *P* \< 0.00001) in the random-effect model as shown in Fig. [6](#Fig6){ref-type="fig"}, and this relationship was a bit stronger in smokers than that in non-smokers.Fig. 6Meta-analysis of the combined effect of ADH1B Arg47His polymorphism and smoking status and esophageal cancer risk under the Arg/Arg versus Arg/His+His/His model

Six articles were selected for gender variance (five for males and two for females). Our result showed that the Arg/Arg genotype of ADH1B Arg47His variant increased the esophageal cancer risk in male patients (OR = 3.44, 95 % CI = 2.42--4.89, *P* \< 0.0001), while not in female patients (OR = 1.62, 95 % CI = 0.90--2.91, *P* = 0.11) as shown in Fig. [7](#Fig7){ref-type="fig"}.Fig. 7Forest plot of the combined effect of ADH1B Arg47His polymorphism and gender variance and esophageal cancer risk under the Arg/Arg versus Arg/His+His/His model (**a** males; **b** females)

Sensitivity analysis and publication bias {#Sec11}
-----------------------------------------

We deleted a single included study at a time to verify whether our results were influenced by each study. The result showed that even though the between-study heterogeneity was reduced, the pooled ORs were not significantly changed, indicating that there was no publication bias in the present meta-analysis. The funnel plot among the total population under the dominant model further reveal no publication bias as shown in Fig. [8](#Fig8){ref-type="fig"}.Fig. 8Funnel plot of the publication bias in this meta-analysis under the dominant model in total population (His/His+Arg/His vs. Arg/Arg)

Discussion {#Sec12}
==========

In this meta-analysis, we totally screened out 23 relevant articles. Our results showed that the ADH1B Arg47His variant was correlated with the decreased occurrence of esophageal cancer under all the genetic models among total population. Subgroup analysis by ethnicity demonstrated that this variant was associated with the decreased cancer risk in Asian populations as well, especially in Chinese and Japanese. However, in non-Asian population, no significant relationship was observed. Furthermore, we found that the combined effect of Arg/Arg genotype in ADH1B Arg47His variant and alcohol drinking, tobacco smoking, and male patients revealed a higher risk on esophageal cancer risk when compared with the His carrier of His/His and Arg/His genotypes, respectively. Our results were consistent with previous meta-analyses which showed that ADH1B\*47Arg could significantly increase the risk of ESCC in Asians, especially when coupled with alcohol drinking \[[@CR29]--[@CR31]\].

Esophageal cancer is considered as a serious malignancy worldwide for its extremely aggressive nature and poor survival rate \[[@CR56]\]. It is a multistep, multifactorial disease, and the incidence is varied due to the geographical diversities; thus, the therapeutic management might be different as well. Genetic variations might be involved in esophageal cancer development and predict the prognosis \[[@CR57]\]. Studies have shown that ADH gene might play a role in carcinogenesis. ADH constitutes a large family of enzymes and is a metabolic barrier against self-administer ethanol \[[@CR58]\]. ADH isoenzyme is responsible for the reversible oxidation of alcohols to acetaldehyde, which is in turn oxidized to aldehyde by aldehyde dehydrogenases (ALD) \[[@CR59]\]. ADH1B and ALDH2 are the major enzymes involved in the alcohol-metabolizing pathways in humans. ADH1B is one member of ADH family and is expressed in the liver and presented in gastrointestinal tract. This gene is mainly contributed for ethanol to carcinogenic metabolite conversion during the elimination phage \[[@CR60]\]. In addition, ADH1B expression could result in high blood acetaldehyde levels, which can easily give rise to DNA damage, and finally cause the cancer occurrence \[[@CR61]\]. Genetic polymorphisms of ADH1B could modulate exposure levels to ethanol. ADH1B can include three alleles (ADH2\*1, ADH2\*2, and ADH2\*3). Among which, the Arg47His variant (ADH2\*2) was the most studied. The activity of ADH1B was increased by 40-fold in ADH1B His/His individuals \[[@CR62]\], resulting in the fast accumulation of acetaldehyde.

SNPs of ADH1B gene (the major alcohol-metabolizing enzyme gene) may modify the effects of alcohol on metabolic and clinical phenotypes \[[@CR63]\]. Blood ethanol concentrations of ADH1B\*2/\*2 group were shown higher than those of ADH1B\*1/\*2 group \[[@CR64]\]. ADH1B allele was associated with a reduction in alcohol consumption \[[@CR65]\] and might be an important protective factor for alcoholic liver cirrhosis, especially for Asians \[[@CR66]\]. ADH2\*2 predicted less drinking and was a protective effect against heavy drinking in Jewish samples \[[@CR67]\]. Heavy alcohol consumption and heavy smoking were shown to be associated with the increased risk of esophageal cancer particularly in individuals with the flushing response \[[@CR68]\].

Previous studies have found that ADH1B Arg47His polymorphism was associated with the pathogenesis of cancers such as colorectal cancer \[[@CR69]\] and head and neck cancer \[[@CR70]\], while no positive correlation was found in hepatocellular carcinoma \[[@CR71]\] and gastric cancer \[[@CR72]\]. Several studies have identified the association between ADH1B polymorphism and esophagus cancer susceptibility. Chen et al. have observed that individuals with ADH1BArg/Arg genotype had a 3.99-fold risk of developing esophageal cancer compared with those with ADH1B His/His genotype \[[@CR73]\]. Li et al. have demonstrated that ADH2\*1 was associated with the increased risk of oesophageal cancer, possibly due to the tolerance of the carriers of these alleles to alcohol consumption compared to those with high-activity alleles ADH2\*2 which are associated with higher production of the unpleasant acetaldehyde intermediate \[[@CR74]\]. Oze et al. found that the magnitude of effect of ADH1B polymorphisms was greater in subjects who were heavy drinkers, heavy smokers, and had esophageal cancer \[[@CR75]\]. Consumption of tobacco and alcohol, coupled with ADH1B genotypes, determines a substantial magnitude of tumorigenetic effect on earlier age ESCC diagnosis \[[@CR76]\].

Several limitations were presented in this meta-analysis. Firstly, most of the included studies were conducted in the Asian population, while other ethnicities should be considered in the future. Secondly, the stages of patients with esophageal cancer could not be extracted from the included studies, which might limit the application of our results. Thirdly, the combined effect of ADH1B Arg47His variant and age group also should be focused on. Lastly, other polymorphisms in ADH1B gene or other ADH genes which might alter the metabolism of alcohol should be included.

Conclusions {#Sec13}
===========

In conclusion, our results suggested that ADH1B Arg47His polymorphism might be a protective factor on esophageal cancer susceptibility in Asians. The Arg/Arg genotypes combined with alcohol drinking, tobacco smoking, and males might be strongly increased the risk of esophageal cancer. However, further studies with more ethnicities should be taken into account in future researches.
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